Those who suffer from chemotherapy-induced peripheral neurotoxicity
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Adult patients who have received chemotherapy and have suffred from CIPN (NCI-CTCAE ver4.0, Grade1, 2, 3) are included. All patients will have written informed consent.
Exclusion criteria
Exclusion criteria: Patients with pre-existing neuropathy, diabetes mellitus, alcoholic abuse or central nervous system metastasis are excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Validation of the point-of-care nerve conduction device for the objective, quantitative assessment of CIPN | — |
Secondary
| Measure | Time frame |
|---|---|
| Correlation of the quantitative assesment of CIPN through the point-of-care nerve conduction device(NC-stat) with the qualitative assesment of CIPN through NCI-CTCAE ver4.0 | — |
Countries
Japan
Contacts
Nagoya University Hospital Department of Clinical Oncology and Chemotherapy